Marker Therapeutics, Inc.
MRKR
$1.21
-$0.07-5.47%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.34M | 3.20M | 3.55M | 4.70M | 5.39M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.34M | 3.20M | 3.55M | 4.70M | 5.39M |
| Cost of Revenue | 8.81M | 11.51M | 11.80M | 14.74M | 15.87M |
| Gross Profit | -6.47M | -9.17M | -9.46M | -11.26M | -11.69M |
| SG&A Expenses | 4.24M | 4.05M | 4.18M | 4.37M | 4.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.05M | 15.55M | 15.98M | 19.11M | 20.07M |
| Operating Income | -10.71M | -13.22M | -13.65M | -15.62M | -15.89M |
| Income Before Tax | -8.72M | -10.91M | -12.18M | -14.25M | -14.56M |
| Income Tax Expenses | -15.20K | -15.20K | -15.20K | 50.00K | 50.00K |
| Earnings from Continuing Operations | -8.71 | -10.90 | -12.16 | -14.30 | -14.61 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.71M | -10.90M | -12.16M | -14.30M | -14.61M |
| EBIT | -10.71M | -13.22M | -13.65M | -15.62M | -15.89M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.47 | -0.66 | -0.90 | -1.23 | -1.36 |
| Normalized Basic EPS | -0.29 | -0.41 | -0.53 | -0.74 | -0.82 |
| EPS Diluted | -0.47 | -0.66 | -0.90 | -1.23 | -1.37 |
| Normalized Diluted EPS | -0.29 | -0.41 | -0.53 | -0.74 | -0.82 |
| Average Basic Shares Outstanding | 74.75M | 69.39M | 61.18M | 51.00M | 43.16M |
| Average Diluted Shares Outstanding | 74.75M | 69.39M | 61.18M | 51.00M | 43.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |